LEAH Labs

LEAH Labs, originally known as Lifengine Animal Health Laboratories, Incorporated, operates out of Rochester, MN, and employs a small team of three. The company is part of the healthcare industry, specifically focusing on therapeutics for pets. LEAH Labs is pioneering the adaptation of CAR-T cell therapy, a method used in human medicine, for treating pets with cancer. This innovative approach involves genetically modifying T immune cells to target and eliminate cancer cells. Currently, LEAH Labs is preparing to enroll dogs with B cell lymphoma in pilot trials set to begin in the first quarter of 2024. These trials will be available to licensed veterinarians and their patients, adhering to the regulations under 9 CFR 103.3. However, it is important to note that the safety and efficacy of these experimental products have not yet been established or approved by the USDA-CVB. The company has garnered support through funding from notable sources including Y Combinator, AgStartup Engine, FIN Capital, Southeast Minnesota Capital, Wefunder, and various angel investors. Additionally, LEAH Labs has received grants from several prestigious organizations such as NSF SBIR, NIH SBIR, LaunchMN, and Regenerative Medicine Minnesota.